title: Inhibition of protein kinase A improves effector function of monocytes from HIV-infected patients.
authors.forename: Tone
authors.initials: T
authors.lastname: Bryn
authors.forename: Milada
authors.initials: M
authors.lastname: Mahic
authors.forename: Einar M
authors.initials: EM
authors.lastname: Aandahl
authors.forename: Stig S
authors.initials: SS
authors.lastname: Frøland
authors.forename: Pål
authors.initials: P
authors.lastname: Aukrust
authors.forename: Kjetil
authors.initials: K
authors.lastname: Taskén
mesh_terms: D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D002478:Cells, Cultured; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors*; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4 / Q000378:metabolism; D015232:Dinoprostone / Q000494:pharmacology*; D005260:Female; D006678:HIV; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D020889:Rolipram / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*
chemical_list: D019380:Anti-HIV Agents; D008070:Lipopolysaccharides; D010726:Phosphodiesterase Inhibitors; D014409:Tumor Necrosis Factor-alpha; D017868:Cyclic AMP-Dependent Protein Kinases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; C517360:PDE4B protein, human; D020889:Rolipram; D015232:Dinoprostone; D015056:1-Methyl-3-isobutylxanthine